Imfinzi & tremelimumab improved OS in liver cancer
15 October 2021 7:00 BST Imfinzi plus tremelimumab significantly improved overall survival in HIMALAYA Phase III trial in 1st-line unresectable liver cancer Trial met primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib Imfinzi monotherapy met the overall survival endpoint of non-inferiority vs. sorafenib Positive high-level results from the HIMALAYA Phase III trial showed a single, high priming dose of tremelimumab added to Imfinzi (durvalumab) demonstrated a statistically significant and clinically